NCT00030550View on ClinicalTrials.gov

Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

September 30, 2001

Primary Completion Date

June 30, 2003

Conditions
LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
Interventions
DRUG

thalidomide

Trial Locations (1)

28412

PPD Development, Wilmington

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Roswell Park Cancer Institute

OTHER

NCT00030550 - Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter